Leerink Partners analyst Geoff Porges maintained a Buy rating on AbbVie (NYSE:ABBV) on Tuesday, setting a price target of $142, which is approximately 29.69% above the present share price of $109.49.
Porges expects AbbVie to post earnings per share (EPS) of $0.42 for the fourth quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Strong Buy rating of shares in AbbVie, with an average price target of $129.27.
The analysts price targets range from a high of $142 to a low of $112.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $13.96 billion and a net profit of $4.54 billion. The company's market cap is $193.49 billion.
According to TipRanks.com, Leerink Partners analyst Geoff Porges is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 1.9% and a 45.95% success rate.
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.